Podcast Episodes
Back to Search282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make the…
2 years, 11 months ago
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the late…
2 years, 11 months ago
280: ESMO highlights, Roivant's big deal, & biotech VC on the rise
Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week's big oncology confere…
3 years ago
Live from the 2023 STAT Summit
Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the se…
3 years ago
278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We …
3 years ago
277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus
It’s Nobel week on the podcast, and reporter Megan Molteni details the unique story of this year’s winners for medicine, Katalin Karikó and Drew Weis…
3 years ago
276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump
Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent…
3 years, 1 month ago
275: A thorny ALS debate at the FDA, and the promise of artificial wombs
Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a…
3 years, 1 month ago
274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
Our colleague Helen Branswell joins us to discuss the state of the Covid-19 pandemic heading into the fall and the rollout of boosters shots aimed at…
3 years, 1 month ago
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters th…
3 years, 1 month ago